Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Rituximab by Biogen for Hairy Cell Leukemia: Likelihood of Approval
Rituximab is under clinical development by Biogen and currently in Phase II for Hairy Cell Leukemia. According to GlobalData, Phase...
Rituximab by Biogen for Neuromyelitis Optica (Devic's Syndrome): Likelihood of Approval
Rituximab is under clinical development by Biogen and currently in Phase III for Neuromyelitis Optica (Devic's Syndrome). According to GlobalData,...
Rituximab by Biogen for Post-Transplant Lymphoproliferative Disorder: Likelihood of Approval
Rituximab is under clinical development by Biogen and currently in Phase II for Post-Transplant Lymphoproliferative Disorder. According to GlobalData, Phase...
MOR-210 by Biogen for Autoimmune Disorders: Likelihood of Approval
MOR-210 is under clinical development by Biogen and currently in Phase I for Autoimmune Disorders. According to GlobalData, Phase I...
Felzartamab by Biogen for Lupus Nephritis: Likelihood of Approval
Felzartamab is under clinical development by Biogen and currently in Phase I for Lupus Nephritis. According to GlobalData, Phase I...
Rituximab by Biogen for Post-Transplant Lymphoproliferative Disorder: Likelihood of Approval
Rituximab is under clinical development by Biogen and currently in Phase II for Post-Transplant Lymphoproliferative Disorder. According to GlobalData, Phase...
BIIB-113 by Biogen for Alzheimer's Disease: Likelihood of Approval
BIIB-113 is under clinical development by Biogen and currently in Phase I for Alzheimer's Disease. According to GlobalData, Phase I...
Rituximab by Biogen for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Rituximab is under clinical development by Biogen and currently in Phase II for Relapsed Chronic Lymphocytic Leukemia (CLL). According to...